title: Cell-mediated and antibody immune responses to AIK-C and Connaught monovalent measles vaccine given to 6 month old infants.
abstract: Measles vaccination of infants younger than 1 year of age should be successful in populations with a high proportion of measles vaccinated mothers. Infants whose mothers were vaccinated are born with less maternal antibody which can interfere with vaccination compared with infants whose mothers had measles. AIK-C or Connaught (CLL) measles vaccine was given to 300 6 month infants born to mothers who had measles (group 1) or who were vaccinated against measles (group 2). Pre- and post-vaccination measles antibody was measured by EIA and PRN and cell mediated immunity (CMI) by blast transformation and production of interferon-gamma and interleukin-10. After vaccination, mean antibody level, seroconversion and blastogenesis were significantly lower for group 1 than group 2 (p < 0.05). Post-vaccination measles IgG was significantly higher for group 2 CLL vaccinees compared with group 2 AIK-C (p < 0.05); seroconversion rates were 73 and 63%, respectively. More than 93% of group 2 infants had elevated measles IgG after vaccination. About 89% of all children had some evidence of a blastogenic response. Lymphoproliferation correlated strongly with cytokine production and weakly with IgG. Not all seroresponders had a CMI response and vice versa. AIK-C and CLL vaccines induce strong measles specific T and B immunity in most 6 month infants of vaccinated mothers.
authors.affiliation: Department of Pediatrics, Walter Mackenzie Centre, University of Alberta, Edmonton, Canada. hpabst@ualberta.ca
authors.forename: H F
authors.initials: HF
authors.lastname: Pabst
authors.forename: D W
authors.initials: DW
authors.lastname: Spady
authors.forename: M M
authors.initials: MM
authors.lastname: Carson
authors.forename: M P
authors.initials: MP
authors.lastname: Krezolek
authors.forename: L
authors.initials: L
authors.lastname: Barreto
authors.forename: R C
authors.initials: RC
authors.lastname: Wittes
mesh_terms: D000914:Antibodies, Viral / Q000097:blood* / Q000276:immunology; D000956:Antigens, Viral / Q000276:immunology; D001402:B-Lymphocytes / Q000276:immunology; D002478:Cells, Cultured; D016207:Cytokines / Q000096:biosynthesis*; D005260:Female; D006801:Humans; D007108:Immune Tolerance; D007112:Immunity, Maternally-Acquired / Q000276:immunology; D007074:Immunoglobulin G / Q000097:blood / Q000276:immunology; D007223:Infant; D007371:Interferon-gamma / Q000096:biosynthesis; D016753:Interleukin-10 / Q000096:biosynthesis; D008213:Lymphocyte Activation; D008457:Measles / Q000276:immunology / Q000821:virology; D008458:Measles Vaccine / Q000009:adverse effects / Q000276:immunology*; D008459:Measles virus / Q000276:immunology*; D009035:Mothers; D013601:T-Lymphocytes / Q000276:immunology; D014611:Vaccination
chemical_list: D000914:Antibodies, Viral; D000956:Antigens, Viral; D016207:Cytokines; D007074:Immunoglobulin G; D008458:Measles Vaccine; D016753:Interleukin-10; D007371:Interferon-gamma